Back

Hepatocellular Carcinoma Kinome Atlas As An Employable Instrumented Personalized Medicine

Kipp, Z. A.; Bates, E. A.; Martinez, G. J.; Lee, W.-H.; Pauss, S. N.; Hinds, T. D.

2025-07-06 pharmacology and therapeutics
10.1101/2025.07.04.25328828 medRxiv
Show abstract

Liver cancer ranks high among cancer death rates and is resistant to most therapies. Studies of protein functionality are limited in patients with hepatocellular carcinoma (HCC). Here, we constructed an HCC kinome activity atlas and used it to develop personalized medicine technology applicable to profiling protein functionality. We used PamGene PamStation kinome technology that quantified protein kinase activity across hundreds of pathways for HCC tumor and non-tumor regions from both sexes. According to our bioinformatic analyses of kinases, ABL was the most active for men and women with HCC. Next, we employed three ABL inhibitors while running the PamStation, which revealed discernible alterations in ABL and other pathways. We deconvoluted over 500 kinase pathways and generated a personalized medicine (PerMed) score delineating activity levels; results were substantiated in five human hepatocyte cancer cell lines. Our work establishes an HCC kinome atlas and demonstrates PamStations potential for precision medicine applications.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.